These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21274757)

  • 1. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial.
    Abd TT; Eapen DJ; Bajpai A; Goyal A; Dollar A; Sperling L
    Curr Atheroscler Rep; 2011 Apr; 13(2):154-61. PubMed ID: 21274757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we measure C-reactive protein on earth or just on JUPITER?
    Bajpai A; Goyal A; Sperling L
    Clin Cardiol; 2010 Apr; 33(4):190-8. PubMed ID: 20394038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of C-reactive protein in patients with stable coronary artery disease: JUPITER in perspective.
    Saely CH; Rein P; Vonbank A; Drexel H
    Int J Cardiol; 2010 Oct; 144(3):448-9. PubMed ID: 19351576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.
    Peña JM; Aspberg S; MacFadyen J; Glynn RJ; Solomon DH; Ridker PM
    JAMA Intern Med; 2015 Feb; 175(2):171-7. PubMed ID: 25437881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
    Scheen AJ
    Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
    Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
    [No Abstract]   [Full Text] [Related]  

  • 8. Is hsCRP Back on Board? Implications from the JUPITER Trial.
    Koenig W
    Clin Chem; 2009 Feb; 55(2):216-8. PubMed ID: 19074517
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
    Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?
    McCormack JP; Allan GM
    PLoS Med; 2010 Feb; 7(2):e1000196. PubMed ID: 20126381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
    Hong YJ; Jeong MH; Hachinohe D; Ahmed K; Choi YH; Cho SH; Hwang SH; Ko JS; Lee MG; Park KH; Sim DS; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2011; 75(2):398-406. PubMed ID: 21157106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JUPITER trial: How will it change clinical practice?
    Watson KE
    Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.
    Narla V; Blaha MJ; Blumenthal RS; Michos ED
    Vasc Health Risk Manag; 2009; 5():1033-42. PubMed ID: 20057896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
    López A; Wright JM
    Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
    Shishehbor MH; Hazen SL
    Cleve Clin J Med; 2009 Jan; 76(1):37-44. PubMed ID: 19122109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Post-JUPITER trial era and the cost of preventive medicine.
    Papadopoulos VP
    Hellenic J Cardiol; 2010; 51(2):187-8. PubMed ID: 20378525
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.
    Kapur NK
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):161-75. PubMed ID: 17338662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of high-sensitivity CRP to predict first cardiovascular events.
    Stahl HD
    Lancet; 2007 Apr; 369(9569):1259-1260. PubMed ID: 17434399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.